Vertical: HealthcareBase Year: 2017
Market Size (2017)
$3.21B
Projected (2023)
$3.98B
CAGR (2015–2023)
4.0%
Key Players
11+
Active pharmaceutical ingredients are used in the manufacturing of pharmaceutical formulations. Duloxetine is a serotonin-norepinephrine reuptake inhibitor used in the treatment of depression and anxiety. Additionally, it is used to help relieve neuropathic pain in people with diabetes or ongoing pain due to medical conditions such as arthritis, chronic back pain, or fibromyalgia. Several factors such as increasing cases of anxiety, the growing prevalence of depression, increasing penetration of generic drugs, the growing trend of outsourcing, strong drug pipeline, and growing demand for newly developed small molecule drugs are anticipated to boost the market growth over the assessment period.
The global duloxetine API was valued at USD 3,213.9 million in 2017, and the market is estimated to grow at USD 3,985.0 million by 2023. In 2017, the Americas accounted for the largest market share of 34.8% with a market value of USD 1,119.1 million, followed by Europe with a market value of USD 975.2 million in 2017.
The global duloxetine API has been segmented based on application and region.
Based on application, the major depressive disorder segment accounted for the largest market share of 33.36% in 2017, with a market value of USD 1,072.1 million, which is projected to register a CAGR of 3.13% during the forecast period.
The Duloxetine API Market market is projected to grow at a CAGR of 4.0% from 2015 to 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDuloxetine is a serotonin-norepinephrine reuptake inhibitor used to treat depression, anxiety, and pain. The growing rates of anxiety, the increasing prevalence of depression, rising penetration of generic drugs, and the growing trend of outsourcing are expected to support the market growth over the forecast period. However, changing economic conditions globally and side-effects of duloxetine are likely to hamper the growth of the global duloxetine API market.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2016
Forecast Period
2018 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global duloxetine API market is dominated by several market players such as Eli Lilly and Company, Apotex Inc., Aurobindo Pharma Ltd, Lupin Ltd, Macleods Pharms Ltd, Shinogi Inc., Sun Pharma Global, Teva Pharms USA, Torrent Pharms Ltd, Zydus Healthcare, Zhejiang Huahai Pharmaceuticals Co., Ltd, Alembic Pharma Ltd, and others. The major players in the duloxetine API market are opting for strategic collaborations and partnerships to brace their position in the market. Moreover, the launch of new products has assisted some major players in gaining a competitive advantage in the market.
Eli Lily and Company is a leading pharmaceutical company that accounted for the largest market share in 2017. The company also has offices in Puerto Rico and 17 other countries. Its products are sold in approximately 125 countries. Lilly was the first company to mass-produce penicillin, the Salk polio vaccine, and insulin. Its achievements include being one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin, Humalog, and the first approved biosimilar insulin product in the US, Basaglar. Lilly is also the world's largest manufacturer and distributor of psychiatric medications including Prozac (Fluoxetine), Dolophine (Methadone), Cymbalta (duloxetine), and Zyprexa (olanzapine).
Lupin held the second largest share of the duloxetine API market in 2017. Moreover, the company holds a 20% market share in the US for duloxetine API. The company manufactures and sells a wide range of Branded and Generic Formulations, Active Pharmaceutical Ingredients (API), Advanced Drug Delivery Systems (ADDS), and biotechnology products in over 100 countries. Its major markets include the US, India, Japan, Europe, South Africa, Philippines, and Australia.
Teva Pharmaceuticals contributed the third largest share for the duloxetine API market in 2017. The company offers its products by utilizing its arrangement of more than 1,800 molecules to create an extensive variety of generic products in almost every therapeutic area. The company is specialized in generic medicines, CNS, brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women's health, and biologics. Geographically, the company operates in regions such as North America, Latin America, Europe, Japan, and South Korea.
Aurobindo Pharma became a public company in 1992 and a market leader in Semi-Synthetic Penicillin. The key therapeutic segments through which the company operates include neurosciences, cardiovascular, anti-retroviral, anti-diabetics, gastroenterology, and cephalosporins, among others. In less than a decade, Aurobindo Pharma has evolved into a knowledge driven-company, manufacturing active pharmaceutical ingredients and formulation products. The company features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations.
Other key companies in the duloxetine API market are Jubilant Life Sciences Limited, Cadila Healthcare Limited, and Cipla USA Inc., among others.
Threat of New Entrants
The threat of new entrants is high in the global duloxetine API market. In Porter’s Five Forces Analysis, the ‘Threat of New Entrants’ refers to the threat that new competitors pose to existing competitors in an industry. A profitable industry will attract more competitors looking to achieve profits. As the number of entrants increases, the profitability of the present players in the industry subsequently decreases. The global duloxetine API market has a high threat of new entrants, threatening the existing players. Moreover, the cost involved in R&D is comparatively high which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
Bargaining power of suppliers in the global duloxetine API market is medium. The bargaining power of suppliers estimates how easy it is for the suppliers to influence the prices of the final products made by innovators. Businesses must obtain the necessary resources that they need from the resource suppliers to carry out their activities.
In the global duloxetine API industry, the number of suppliers is comparatively less than the number of firms operating in the sector, and only a few of them have a large hold on the duloxetine API market. The recessionary pressures have reduced the price of many components and raw materials due to downward demand trends. Moreover, the switching cost of these suppliers is also medium as the suppliers tend to enter long-term associations with the manufacturers.
Threat of Substitutes
The threat of substitutes in the global duloxetine API market is medium to low. The substitute to the duloxetine API can only be in the form of large molecules. Buyer propensity to substitute is moderate due to the lesser availability of substitutes in this market. In addition, the high degree of switching cost minimizes the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of the buyer is considered to have a low impact on the industry. The bargaining power of the buyers evaluates how easy it is for the buyers to affect the price of pharmaceutical products. There is a low number of players with capabilities to manufacture high-end drugs.
Also, the high differential advantage of the duloxetine API market coupled with low or poor existing substitutes for high tech products makes the position of the manufacturers strong. However, the latest trend of mergers between large healthcare providers coupled with strategies such as demand pooling by multiple players is increasing the power of the buyers.
Intensity of Rivalry
The degree of competition in the global duloxetine API market is high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. The intensity of competitive rivalry evaluates the capability and the level of rivalry among competitors in the market. It also refers to the extent to which firms within an industry put pressure on one another and limit each other’s profit potential. Rivalry among industry players can affect industry profits through downward pressure on prices, increased innovation, increased advertising, and increased service/product improvements, among others.
Market estimates by geography (2023)
InsightAmericas leads with $1.40B by 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $199.60M | $239.40M | $257.10M | 3.2% | 6% |
| Americas | $1.00B | $1.22B | $1.40B | 4.3% | 35% |
| Asia Pacific | $827.10M | $964.40M | $1.15B | 4.2% | 29% |
| Europe | $878.00M | $1.06B | $1.17B | 3.7% | 29% |
| Total | $2.91B | $3.49B | $3.98B | 4.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Duloxetine API Market covering market dynamics, competitive landscape, and strategic outlook.
The Duloxetine API Market market is projected to reach $3.98B by 2023, growing at 4.0% CAGR.
The duloxetine drug primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), and pain related to diabetic peripheral neuropathy, among others. Factors such as the rising rates of anxiety cases, increasing prevalence rates of depression, increasing penetration of generic versions of drugs, strong drug pipeline, growing demand for newly developed small molecule drugs, and the growing trend of outsourcing are major drivers propelling market growth.
The people suffering from anxiety are increasing at a fast pace. According to a report by the World Health Organization (WHO), the portion of the global population with anxiety disorders was estimated to be 3.6% in 2015. It also stated that in 2015 the total estimated number of people living with anxiety disorders globally was about 264 million. According to the same source, in 2015, about 36.17 million cases of anxiety disorders were reported in the European region. Moreover, according to the updated report by the Anxiety and Depression Association of America, in 2017, approximately 30% of the adult population in North America had anxiety disorders. Therefore, as duloxetine is used to treat anxiety cases, the increasing prevalence of anxiety is expected to provide favorable background for the market to grow over the forecast period.
Over the past years, the pharmaceutical industry has been focusing more on the development of biologics. As a result, the API market has suffered tremendous regression. Many custom manufacturing organizations (CMOs) have shifted their focus to high-value biologics manufacturing.
Nevertheless, the attention of the pharmaceutical industry seems to be back with small molecule therapeutics. Many companies have come up with generic versions of duloxetine. For instance, in June 2014, Dr. Reddy's Laboratories launched duloxetine delayed-release capsule United States Pharmacopeia (USP) 20 mg, 30 mg, and 60 mg in the US market. Thus, the growing worldwide demand for effective drugs and the upcoming launch of several blockbuster drugs would create more opportunities in the near future.
Austerity measures in Europe are putting pressures on margins for drug manufacturers. For instance, in the past, Germany has implemented a free price-setting mechanism which had led pharma companies to enjoy high prices of patented pharmaceutical products. But since the economic downfall in the region, Germany started seeking chances to curb its expenses and to control the increasing pharmaceutical spending. The country passed the act for restructuring the pharmaceutical market in statutory health insurance which came into effect in 2011. According to the regulation, pharmaceutical manufacturers must demonstrate the additional therapeutic benefit of newly approved pharmaceuticals compared to their competitors.
Furthermore, German drug prices are frequently used as a reference point by healthcare providers in other European countries. This has put severe pricing pressures on drug manufacturers which led many to look for alternative ways to decrease their cost of manufacturing to survive in the harsh market. The economic condition in Europe is a major factor of worry for the growth of the global duloxetine API market.
Pricing is one of the most important factors for a product to survive in the market. The price of the duloxetine API deviates according to the cost of raw material, the technology used, cost of research and development, labor charges, and the country regulations, among others. Furthermore, the market is driven by the demand for quality products with high purity level. Key players enjoy economies of scale. Also, after the loss of Cymbalta (duloxetine) patent in 2013, a lot of generic API manufacturers entered the market. Thus, the price for API dropped considerably. Furthermore, the purity grade of the chemicals highly influences the overall cost of the active pharmaceutical ingredient. There are various generic manufacturers which develop low grade as well as high grade duloxetine API. Thus, the price fluctuates depending upon the purity.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 106 companies operating in the Duloxetine API Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
Zydus Lifesciences is transitioning from a volume generics exporter into a branded, innovation-weighted global life-sciences company. Management states that branded products now exceed 55% of consolidated revenue and that branded sales within the United States have reached 11% (Q1 FY27). The company is the third-largest generic pharmaceutical company in the US by prescription volume, holds a top-tier position in Indian branded formulations with leadership in oncology, and owns India's most commercially credible new-chemical-entity franchise in Lipaglyn (saroglitazar) and Oxemia (desidustat). FY26 revenue of ₹27,148 crore (~US$3.07 billion) was the company's highest ever, with a record 31.2% EBITDA margin. Three inorganic moves in eighteen months — Comfort Click in consumer wellness, Amplitude Surgical in orthopaedic devices, Agenus' California biologics plants and Assertio in US specialty oncology — have simultaneously diversified the earnings base and, for the first time in a decade, levered the balance sheet. The central investment question is whether specialty and biosimilar scale-up outruns Revlimid and Mirabegron erosion. Zydus Lifesciences Limited is the listed flagship of the Ahmedabad-based Zydus Group and India's fifth-to-sixth largest pharmaceutical company by revenue. It is a vertically integrated, increasingly innovation-led life-sciences business spanning branded formulations in India, generics and specialty pharmaceuticals in North America, emerging-market and European formulations, active pharmaceutical ingredients, consumer wellness (through the separately listed subsidiary Zydus Wellness), medical technology, vaccines, biosimilars and — since January 2026 — US-based biologics contract manufacturing. --- **What the company does.** Zydus discovers, develops, manufactures and markets a broad range of healthcare therapies: small-molecule generics, branded prescription formulations, biologics and biosimilars, vaccines, active pharmaceutical ingredients, consumer wellness products, and — most recently — orthopaedic implants and biologics contract manufacturing services. The company's own framing, repeated verbatim in its earnings releases, is that of "an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies," operating under "an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives." **Independent characterisation.** Zydus is best understood as four businesses of very different economic character stapled to a common Indian manufacturing and R&D base: 1. **A US generics volume machine (~40-44% of revenue).** Commodity-priced, high-working-capital, exposed to distributor consolidation and price erosion, but defended by scale — 513 cumulative ANDA filings and 448 approvals as at 30 June 2026 — and by first-to-file/CGT exclusivity opportunism. Earnings here are lumpy and event-driven, dominated in recent years by generic Revlimid (lenalidomide) and generic Myrbetriq (mirabegron), both of which are now rolling off. 2. **An Indian branded prescription franchise (~24-25% of revenue).** Annuity-like, chronic-weighted, priced above generics, with distribution scale and physician relationships as the moat. Chronic and sub-chronic therapies reached 54.2% of the India book by MAT June 2026 (AWACS), up 360 basis points over four years. 3. **A consumer wellness FMCG business (~15-20% of revenue).** Held through the separately listed Zydus Wellness Limited. Brand-driven, seasonal, low regulatory risk, and — since Comfort Click — increasingly a cross-border e-commerce/D2C vitamins business rather than a purely Indian one. 4. **An emergent specialty/innovation portfolio.** Rare disease (Zycubo, Nulibry via Sentynl), 505(b)(2) reformulations (Beizray), biosimilars (Nufymco, Tishtha, Anyra), NCEs (saroglitazar, desidustat, zintrodiazine), MedTech (Amplitude Surgical) and CDMO (Zylidac Bio). This is where management is directing incremental capital, and where none of the assets is yet individually material to consolidated revenue. **Revenue model.** Overwhelmingly product sales rather than services or subscription. Three secondary streams exist: (a) out-licensing income — desidustat was licensed to China Medical System Holdings in 2020 and reached Chinese approval in FY26; (b) alliance/contract income, reported as "Alliances & Others" and now near-immaterial at ₹571 million in FY26 (down 64% year on year); and (c) from FY27, contract development and manufacturing fees through Zylidac Bio LLC, which carries an exclusive manufacturing arrangement with Agenus for botensilimab and balstilimab plus a first right of negotiation on Agenus' future pipeline. **Value chain position.** Unusually integrated for an Indian pharmaceutical company: captive API manufacture (with the pending Sterling Biotech API acquisition intended to deepen this), formulation manufacture across 44 facilities, in-house biologics drug substance and drug product capability, its own US front-end distribution (Zydus Pharmaceuticals USA, Viona, Sentynl, Zydus Therapeutics), and now US-domiciled biologics manufacturing. **Customer types and end-markets.** In India: distributors and stockists selling into ~800,000 retail pharmacies, plus hospitals and institutional/government tenders (notably vaccines). In the US: the three large drug purchasing consortia and wholesalers (whose bargaining power drives the group's 188-day gross current asset cycle), plus specialty pharmacy and buy-and-bill oncology channels for Rolvedon and the biosimilars. In emerging markets and Europe: a mix of own subsidiaries (France, Spain, Brazil, South Africa, Mexico, Philippines, Sri Lanka, Myanmar) and third-party distributors. In consumer wellness: modern trade, general trade, e-commerce and, post-Comfort Click, direct-to-consumer digital channels in the UK, EU and US.
Company Headquarters: Hyderabad, Andhra Pradesh Founded: 1986 Workforce: 5,001-10,000 Company Working: Aurobindo Pharma is a vertically integrated pharmaceutical company that delivers innovative solutions. The company manufactures and sells over 300 products in over 150 countries across the globe through six major therapeutic segments such as antibiotics, anti-retroviral, CVS, CNS, gastroenterological, and anti-allergic. Through cost-effective manufacturing capabilities and a few loyal customers, the company has entered into the high margin specialty generic formulations segment. Aurobindo Pharma has evolved into a knowledge-driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries.
Company Headquarters: Osaka, Japan Founded: 1878 Company Working: Shionogi Inc. is a development organization capable of conducting multiple simultaneous late-stage clinical programs and submitting new drug application (NDA) filings worldwide. The company has established commercial capabilities to market their products globally effectively.
Company Headquarters: Canada Founded: 1974 Workforce: 10,000+ Company Working: Apotex Inc. (Apotex) is the largest Canadian-owned pharmaceutical company. It is also the largest producer of generic medicines in the country. Apotex is a global, fully integrated API R&D company. It has many facilities across the globe located in Canada, India, Mexico, and China. The Apotex Group of Companies is comprised of Apotex Generics, Apotex Active Pharmaceutical Ingredients, Apobiologix, and ApoPharma (Innovative Products) through vertical integration. The company exports to more than 115 countries and operates in more than 45 countries. Globally, it produces approximately 25 billion doses per year, which are used to fill over 89 million prescriptions in Canada alone. Apotex is into unit dose products, injectable products, and specialty products.
Company Headquarters: Hyderabad, India Founded: 1997 Workforce: 10 Company Working: Hetero is a research-based global pharmaceutical company focused on the development, manufacturing, and marketing of active pharmaceutical ingredients (API), intermediate chemicals, and finished dosages. The company is vertically integrated for research discovery, process chemistry, API manufacturing, formulation development, and commercialization. It is an international supplier of over 200 products from a wide range of therapeutic categories. Majority of them are approved by various regulatory authorities of the USFDA, WHO-Geneva, Australian TGA, Spanish agency of medicines & health care products, ANVISA-Brazil, IDA-Netherlands, etc. It markets its products in over 138 countries across the globe.
Company Headquarter: Mumbai, India Founded: 1968 Workforce: 15,000+ Company Working: Lupin is a global pharmaceutical company that deals in a wide range of products such as branded and generic formulations, biotechnology products, APIs, and specialty drugs. The company is a prominent player in the therapeutic segment such as gynecology, cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal (GI), anti-infective (AI), and non-steroidal anti-inflammatory drugs (NSAIDS). Also, it has a global leader in the fields of the anti-TB and Cephalosporin segment. Lupin has a presence in more than 100 countries. It has 18 manufacturing facilities, located in many parts of India, Japan, the US, Mexico, and Brazil. All these facilities are benchmarked to international standards to meet stringent quality standards. Also, these facilities are approved by international agencies such as the US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and the MCC South Africa.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
